Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease symbols : PHAT save search
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
Published: 2023-05-09 (Crawled : 12:00) - globenewswire.com
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 0.73%
H: 0.56%
C: -3.54%
week disease pharmaceuticals
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
Published: 2023-01-08 (Crawled : 00:00) - globenewswire.com
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 0.8%
H: 13.19%
C: 2.51%
nerd-301 pharmaceuticals disease topline trial positive
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
Published: 2022-10-24 (Crawled : 14:00) - biospace.com/
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 0.7%
H: 1.64%
C: -3.68%
nerd-301 pharmaceuticals disease trial
Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022
Published: 2022-05-24 (Crawled : 17:00) - globenewswire.com
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: -7.97%
H: 0.0%
C: 0.0%
week disease
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)
Published: 2022-02-09 (Crawled : 22:00) - globenewswire.com
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: -0.64%
H: 10.37%
C: 9.25%
phase 2 als trial disease topline results positive topline
Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)
Published: 2020-12-14 (Crawled : 14:01) - globenewswire.com
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 2.0%
H: 2.87%
C: -4.22%
disease program
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.